This record was last updated July 9, 2025 (before its estimated October 2025 completion). Its status may not reflect the trial's current state.
Summary
Expression of ER, PR and HER2/neu in initial and recurrent breast cancer and correlate the results to different clinical and pathological parameters as patient age,sex, tumor location, status of nodal involvement and lymphovascular invasion